MedPath

Success Rate of 4 Injection Protocols for Mandibular First Molars With Symptomatic Irreversible Pulpitis

Not Applicable
Completed
Conditions
Root Canal Infection
Interventions
Procedure: local anesthesia
Registration Number
NCT04929522
Lead Sponsor
Ain Shams University
Brief Summary

Achieving profound anesthesia during endodontic treatment of mandibular molars with symptomatic irreversible pulpitis is still a demanding clinical challenge. therefore, the success Rate of 4 Injection protocols for Mandibular First Molars with Symptomatic Irreversible Pulpitis was evaluated clinically in a randomized triple-blind trial

Detailed Description

Trial design This study was a prospective, randomized, parallel, triple blinded, clinical trial. The present trial design methodology conforms to the CONSORT guidelines for reporting randomized clinical trials.Participants A sample size calculation was performed based on the study by (Kanaa M, Whitworth JM, Meechan JG. A Prospective Randomized Trial of Different Supplementary Local Anesthetic Techniques after Failure of Inferior Alveolar Nerve Block in Patients with Irreversible Pulpitis in Mandibular Teeth. J Endod 2012;38:421-425). This research was based on a type I error of 0.05 and a power of 0.8 and indicated that ideally a sample size of 36 in each group would be required to detect a 20% difference in the success rate of the test groups. To increase the validity of the study, 40 subjects in each group were considered.Ethical considerations This trial was conducted with the approval of the institutional review of board (IRB) of the ethics committee at the Faculty of Dentistry, Ain Shams University, Cairo, Egypt (FDASU-REC 772019). Patients signed a printed informed consent form after explanation of the treatment procedure and associated possible adverse effects of the proposed interventions such as discomfort, pain, anesthetic failure and systemic side effects at this stage. Randomization To ensure random selection, participants were allocated randomly into four groups with1:1 allocation ratio by using computer generated randomization (www.randome.org). The sequence was therefore generated.

Allocation concealment mechanism: The sequentially generated numbers were placed in opaque envelopes until the intervention was conducted, and each participant was asked to select an envelope that determines which group of intervention was assumed.

Implementation: Co-researcher used computer generated randomization for participants who achieve eligibility criteria and accordingly participants were enrolled in either of the groups under study.

Blinding Both the participants, the operator who initiated endodontic treatment and monitored the pain, and the statistician were blinded to the anesthetic techniques used.

Intervention Diagnosis was confirmed through history reporting spontaneous pain, a moderate to severe painful response that persists after thermal stimulation, a prolonged response to cold testing with Endo-Ice (1,1,1,2 tetrafluoroethane; Hygenic Corp, Akron, OH), absence of percussion sensitivity and the periapical aspect of the tooth in the bidimensional periapical radiograph was normal. Matching vital contralateral teeth were also tested to ensure an accurate diagnosis and to serve as controls. To prevent bias, this diagnostic step was performed by one investigator (AH), while another investigator (DK) was responsible for administration of all anesthetic injections (DK), and a third investigator (SS) was responsible for root canal treatment procedures and pain recording. All investigators have a minimum of 12 years of clinical experience in endodontics.

One hundred and eighty-five patients consecutively visited were assessed for eligibility. Twenty-five patients were excluded for different reasons and the others (eighty-four female and seventy-six male patients) were allocated to the trial (Figure 1) and randomly assigned into 4 groups (n=40) as follows:

Group 1 (IANB): After determining the injection site and aspiration, 3.6ml of the anesthetic solution was administered using the standard inferior alveolar nerve block (IANB), this was considered the control group.

Group 2 (IANB + IO): A standard IANB was administered the same as for Group 1, followed by a supplemental intraosseous infusion (IO) injection using the Anesto system (W\&H Dentalwerk Bürmoos, Austria). To ensure comfort during the procedure, 0.1ml of anesthetic solution was infiltrated at the perforation site using the standard syringe. The perforation site was selected near the junction of the attached and unattached gingival tissues, immediately distal to the first molar. Perforation was accomplished by operating the Anesto handpiece at full speed, with constant moderate pressure maintained until the perforator was felt to 'drop' into the cancellous bone. 1.8mL of the anesthetic solution was then deposited over a 60-second period. The Anesto handpiece was again retracted and, with the perforator rotating, removed from the injection site.

Group 3 (IANB + PDL): A standard IANB was administered the same as for groups 1 and 3, followed by a supplemental periodontal ligament (PDL) injection. The needle was wedged with force into the PDL space between the tooth and the alveolar crest of the bone, at 30-degrees to the long axis of the tooth. The thumb and index fingers of the left hand supported the needle to prevent buckling. The handle of the syringe was squeezed firmly until backpressure was achieved. Then a total of 1.8ml of the anesthetic solution were injected mesially and distally to the treated molar.

Group 4 (IANB + BI): A standard IANB was administered the same as for groups 1, 2 and 3, followed by a supplemental buccal infiltration at the buccal side of the affected tooth. A total of 1.8ml of the anesthetic solution were injected halfway the mesiodistal width of the clinical crown.

IANB, PDL and BI injections were performed with a conventional dental syringe (indicate the brand) and a 27-G needle at a rate of 2 mL/min. The anesthetic solution used for all techniques was Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain). The efficacy of anesthesia was determined by the following: (1) confirmation of lip numbness, (2) negative response to Endo-Ice, (3) negative response to the maximum output of the electric pulp tester (Parkell, Edgewood, NY, USA).

Root canal treatment procedure was later initiated, and the patients were asked to rate their pain using a visual analogue scale (VAS). Pain was scored as follows: Score 0, no pain; Score 1, mild pain; Score 2, moderate pain; or Score 3, severe pain. After rubber dam placement and during caries removal, access preparation and pulpectomy, success of the anesthetic technique was determined by VAS. The technique was considered as a 'success' when the patient reported no pain (VAS = 0 or 1) and as a 'failure' otherwise (VAS \>1).

Heart rate changes were monitored with a finger pulse oximeter (Medlinket, Shenzhen Med-link Electronics, Shenzhen, China). It was recorded from 2 min before to 5 min after injection, at 30-s intervals. The mean heart rate for each injection was recorded.

Statistical analysis All analyses were undertaken with IBM SPSS Statistics (SPSS 26.0; SPSS Inc., Chicago, IL). The anesthetic success rates were analyzed using the chi-square test. Age differences were analyzed using One Way ANOVA, gender differences were analyzed using the Fischer Exact test while heart rate changes were analysed with Kruskal Wallis test, being non-normally distributed. Statistically significant differences were set at the P \< 0.05 level

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
160
Inclusion Criteria
  • Patients included in the study were healthy males and females
  • (Category: American Society of Anesthesiologists class 1)
  • aged 21-49 years
  • with no physical disability, facial paresthesia or psychological problems
  • presenting with a single vital mature mandibular first molar, with signs and/or symptoms of symptomatic irreversible pulpitis
Read More
Exclusion Criteria
  • Pregnant women
  • patients who took analgesics or other medications that would alter the inflammatory response of the pulp or provide analgesia 6- hours pre-operatively
  • those with known sensitivity to the pharmaceuticals used in this trial.
  • those with pathological periodontal pockets
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
IANB+PDLlocal anesthesiapatients will be given standard IANB plus a PDL injection with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
IANB+BIlocal anesthesiapatients will be given standard IANB plus a BI injection with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
IANB/inferior alveolar nerve blocklocal anesthesiapatients will be given standard IANB with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
IANB+IOlocal anesthesiapatients will be given standard IANB plus an intra-osseous with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
Primary Outcome Measures
NameTimeMethod
Number of Participants With Successful Injection Technique Assessed by Verbal Rating Scale (VRS)15 minutes from delivery of anesthesia

the patients were asked to rate their pain using a Verbal rating scale (VRS). Pain was scored as follows: Score 0, no pain; Score 1, mild pain; Score 2, moderate pain; or Score 3, severe pain. After rubber dam placement and during caries removal, access preparation and pulpectomy, success of the anesthetic technique was determined by NRS. The technique was considered as a 'success' when the patient reported no pain (VRS = 0 or 1) and as a 'failure' otherwise (vRS \>1).

Secondary Outcome Measures
NameTimeMethod
Changes in the Heart Rate Before, During and After the Injectionassessed from 2 min before to 5 min after injection (at 30-s intervals)

beat per minute measured by a finger pulse oximeter

Trial Locations

Locations (1)

Ain Shams University

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath